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HMG CoA reductase inhibitors (statins) are known to prevent cardiovascular disease and
improve lipid profiles. However, the effects of statins on renal outcomes, including decline in
estimated glomerular filtration rate (eGFR) and proteinuria in patients with chronic kidney
disease (CKD), are controversial. This meta-analysis evaluated the impact of statins on
renal outcomes in patients with CKD.
Materials and Methods
We comprehensively searched the databases of MEDLINE, EMBASE, and Cochrane Data-
bases. The inclusion criteria were published RCT and cohort studies comparing statin ther-
apy to placebo or active controls in patients with CKD (eGFR <60 ml/min/1.73 m2) not
requiring dialysis. The primary outcome was the differences in the change of eGFR. We
also examined change of protein concentration in urine as a secondary outcome. A meta-
analysis comparing statin and its control groups and a subgroup analysis examining inten-
sity of statin were performed.
Results
From 142 full-text articles, 10 studies were included in the meta-analysis. Overall, there was
a significant difference in rate of eGFR change per year favoring statin group (mean differ-
ence (MD) = 0.10 ml/min/1.73 m2, 95% CI: 0.09 to 0.12). In our subgroup analysis, those
who received high-intensity statins had a significant difference in eGFR with a MD of 3.35
(95% CI: 0.91 to 5.79) ml/min/1.73 m2 compared to control. No significant change in eGFR
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was found with moderate- and low-intensity statin therapy. Compared with the control
group, the statin group did not have a difference in reduction of proteinuria with MD in
change of proteinuria of 0.19 gm/day (95% CI: -0.02 to 0.40).
Conclusion
Overall, there was a difference in change of eGFR between the statin and control group.
High-intensity statins were found to improve a decline in eGFR in population with CKD not
requiring dialysis compared with control, but moderate- and low-intensity statins were not.
Statins were not found to decrease proteinuria in patients with CKD.
Introduction
Chronic kidney disease (CKD) is an important cause of death worldwide, affecting more than
10% of the population [1]. One of the risk factors for developing CKD and worsening renal
outcomes is renovascular disease. One of the proposed mechanisms for progressive CKD in
patients with renovascular disease is endothelial dysfunction, oxidative stress, and systemic
inflammation of the glomerular capillary wall [2].
There is evidence that statins may improve renal function and lower proteinuria in many
prospective cohort studies, randomized-control trials and meta-analyses [3–5]. This could be
due to statin’s effects of decreased inflammation and improvement of endothelial function [6].
However, previous meta-analyses on the effect of statins on renal outcomes were not specifi-
cally done in CKD population [7]. One meta-analysis analyzed only the renal outcome at the
end of treatment and did not examine change in renal function from baseline. Thus, the impact
of statins on change in renal function in CKD patients is still unclear [8]. In addition, since the
American College of Cardiology/American Heart Association (ACC/AHA) Guidelines [9]
have emphasized different statin intensities in patients with different risk of atherosclerotic car-
diovascular disease, we hypothesized that there is a dose-response relationship between statin
intensities and renal outcome. Therefore, we conducted a systemic review with a meta-analysis
of cohort studies and randomized-controlled trials to determine the effects of statins on change
in renal function and protein excretion compared with controls in patients with CKD [10].
Materials and Methods
This systematic review and meta-analysis was conducted and reported according to established
guidelines [11,12] (S1 Appendix) and was registered in PROSPERO (registration number:
CRD42014013047).
Search Strategy
Two authors (AS and SU) independently searched published studies indexed in the Cochrane
Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, and
EMBASE from January 1995 to January 2015. There were no limitations on language or publi-
cation date. References of selected retrieved articles were also examined. Sample search terms
were: “statin”, “Hydroxymethylglutaryl-CoA Reductase Inhibitors”, “hmg coa reductase inhibi-
tor”, “chronic renal insufficiency”, “kidney failure”, “CKD”. We limited searches to human
only. We did not use filter for study design or limit for adults. Search terms that were used are
detailed in S2 Appendix.
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Inclusion and exclusion criteria
We included all published randomized clinical trials (RCTs), prospective cohort and retrospec-
tive cohort studies comparing statins with placebo or no statin therapy for at least 6 months in
patients with chronic kidney disease. We included cohort studies to explore renal outcomes
and potential side effects from statin use. We excluded reviews, case reports, letters, commen-
taries, abstracts, and unpublished articles.
We included participants aged 18 years or older who had CKD stages 3 to 4 (defined as
eGFR 15–59 ml/min/1.73 m2) and had a baseline eGFR, creatinine clearance or protein con-
centration in urine. Participants who received dialysis, renal replacement therapy or renal
transplantation were excluded from the analysis.
Primary outcome was change of eGFR or creatinine clearance from baseline. Secondary out-
comes were change in urinary protein concentration, incidence of 50% reduction in eGFR, and
incidence of ESRD.
Data Extraction
Two authors (AS and SU) independently reviewed titles and abstracts of all citations that were
identified. After all abstracts were reviewed, data comparisons between investigators were con-
ducted to ensure completeness and reliability. The inclusion criteria were independently
applied to all identified studies. Differing decisions were resolved by consensus.
Full-text versions of potentially relevant papers identified in the initial screening were
retrieved. If multiple articles from the same study were found, only the article with the longest
follow-up period was included. Data concerning study design, participant characteristics, inter-
ventions, and outcome measures were independently extracted. We contacted the authors of
the primary reports to request any unpublished data. If the authors did not reply, we used the
available data for our analyses.
Assessment of Bias Risk
A subjective assessment of methodological quality for RCT’s was conducted by two authors
(AS and SU) on the following items, in which each component was categorized as having high,
low or unclear risk of bias: random sequence generation, allocation concealment, blinding of
participants and personnel, blinding of outcome assessment, incomplete outcome data, and
selective reporting. The quality of cohort studies was evaluated by the same authors using the
Newcastle-Ottawa Scale (NOS) [13]. The NOS is a quality assessment tool for non-randomized
study. It used a “star system” based on three major perspectives: the selection of the study
groups (0–4 stars), the comparability of the groups by controlling for first and second most rel-
evant factors (0–2 stars), and the ascertainment of outcome of interest (0–3 stars). A total score
of 3 or less was considered poor, 4–6 was considered moderate, and 7–9 was deemed high qual-
ity. We excluded studies from our meta-analysis if they had poor quality. Discrepant opinions
between authors were resolved by consensus.
Statistical Analysis
We performed meta-analysis of RCT and cohort studies separately. We reported the pooled
mean difference (MD) of a total change in eGFR, proteinuria, rate of change in eGFR per year
between statin group and controls. Pooled risk ratio (RR) of 50% reduction of eGFR and inci-
dence of ERSD were also reported. For the purpose of our meta-analysis, creatinine clearance
was considered to be equivalent to eGFR. The extracted studies were excluded from the analysis
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if they did not present an outcome in each of the intervention groups or did not have enough
information required for continuous data comparison.
We also performed a subgroup analysis of statin intensity, which was characterized as
“high-intensity”, “moderate-intensity”, and “low-intensity” statin therapy, using definitions
from the recent ACC/AHA guidelines (9). High intensity statins lower LDL-C by
approximately  50%, include atorvastatin 40–80 mg and rosuvastatin 20-(40) mg. Moderate-
intensity statins lower LDL-C by approximately 30% to<50%, include atorvastatin 10-(20)
mg, rosuvastatin (5)-10 mg, simvastatin 20–40 mg, pravastatin 40-(80) mg, lovastatin 40 mg,
fluvastatin XL 80 mg, fluvastatin 40 mg bid, pitavastatin 2–4 mg. Low-intensity statins lower
LDL-C by approximately<30%, include fluvastatin 20–40 mg, lovastatin 20 mg, simvastatin
10 mg, pitavastatin 1 mg, pravastatin 10–20 mg. Statin and doses that are approved by the U.S.
FDA but were not tested in the RCTs reviewed in the guidelines are listed in parentheses.
The heterogeneity of effect size estimates across these studies was quantified using the I2 sta-
tistic and Q statistic. For Q statistic, substantial heterogeneity was defined as P<0.1. The I2 sta-
tistic ranges in value from 0 to 100% (I2<25%, low heterogeneity; I2 = 25%–50%, moderate
heterogeneity; and I2>50%, substantial heterogeneity). A sensitivity analysis was performed to
assess the influence of the individual studies on the overall results by omitting one study at a
time. Meta-regression was performed to find source of heterogeneity and to assess association
between baseline LDL-C or percent reduction in LDL-C in the statin group and difference in
eGFR change. Possible publication bias was assessed using funnel plot and Egger’s regression
test [14] (P<0.05 was considered significant). All data analyses were performed using the Com-
prehensive Meta-Analysis 3.3 software from the Biostat, Inc.
Results
Description of Included Studies
The initial search yielded 4,291 articles (Fig 1); 4,141 articles were excluded because they were
not RCTs or observational studies (1,866 articles), did not involve CKD participants (1,426
articles), included dialysis patients or did not have primary outcome (849 articles). A total of
150 articles underwent full-length review. Data were extracted from ten studies involving total
of 18,126 CKD participants for qualitative analysis [15–24]. The included studies varied in
sample size (38 to 6,245), type and dose of statins used (Fluvastatin 20 mg, Pravastatin 40 mg,
Atorvastatin 40–80 mg, Lovastatin 40 mg, and Rosuvastatin 2.5 mg), and duration of treatment
(12–64 months). Among the ten included studies, nine were RCT’s, and one was a prospective
cohort study. Sample size of the included studies ranged from thirty-eight to 6,245. Low, mod-
erate and high-intensity statins were all used in the included studies. The study duration ranged
from twelve to sixty-three months. LDL-C reduction from baseline ranged from 7.6% to 40.4%.
The characteristics of the ten extracted studies included in this review are outlined in Table 1.
Of these, six studies were included in the meta-analysis for difference in eGFR change
[15,18,20,21,22] and rate of eGFR change per year [16,17,19,20,24]. Three studies were
included in the analysis of difference in proteinuria [15,22,24]. Two studies were included in
analysis comparing 50% reduction of eGFR and incidence of ESRD [20,24]
Risk of Bias of Included Studies
All RCT and non-randomized prospective controlled studies were assessed for risk of bias
(summarized in S1 Fig). About one-fourth of the studies had selection bias because of non-ran-
domization or no allocation concealment. In addition, only one-third of studies were double-
blinded and had blinding of outcome assessment. The quality of one prospective cohort study
Statins in Chronic Kidney Disease
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[23] was evaluated by NOS. It received a total of 8 stars (4 stars for selection, 2 stars for compa-
rability, and 2 stars for ascertainment of outcome).
Meta-analysis Results
We performed this meta-analysis to investigate the effects of statins versus placebo or control
on eGFR and proteinuria using a random effects model. Since there is only one prospective
Fig 1. Results of Information Search.
doi:10.1371/journal.pone.0132970.g001
Statins in Chronic Kidney Disease































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Statins in Chronic Kidney Disease



























































































































































































































































































































































































































































































































































































Statins in Chronic Kidney Disease
PLOS ONE | DOI:10.1371/journal.pone.0132970 July 7, 2015 7 / 13
cohort study [23], only RCTs were included in the meta-analyses. There was significant differ-
ence in the change in the average end of treatment eGFR for rate of eGFR change per year, but
no difference the total change of eGFR (Fig 2A and 2B). The MD of rate of eGFR change per
year was 0.10 ml/min/1.73 m2 (95% confidence interval [CI]: 0.09 to 0.12). The statistical
between-study heterogeneity was absence (I2 = 0%, p-value = 0.60). The MD of total change in
eGFR was 1.78 ml/min/1.73 m2 (95% CI: -0.26 to 3.81). The statistical between-study heteroge-
neity was statistically significant with an I2 of 98% (p-value<0.01).
A meta-analysis of studies examining change in proteinuria was also performed (S2 Fig).
There was no significant change in urinary protein excretion with a MD of 0.19 gm/day (95%
CI: -0.02 to 0.40). There was significant heterogeneity between the included studies in this
meta-analysis (I² = 90%).
Only two studies were included in the analysis of comparison in incidence of ESRD and
50% reduction of eGFR or ESRD between statin and control groups. There were no significant
association between statin group and control with ESRD (RR = 0.97, 95% CI: 0.90 to 1.06), and
50% reduction of eGFR (RR = 0.93, 95% CI: 0.86 to 1.01) (S3A and S3B Fig).
The results of our subgroup analysis of statin intensity is shown (Fig 3). There was a signifi-
cant increase in eGFR in studies of high-intensity statin (LDL-C reduction = 34%-40%) com-
pared with control: the MD of total change in eGFR was 3.35 ml/min/1.73 m2 (95% CI: 0.91 to
5.79). No statistically significant difference of change in eGFR was found with moderate-
Fig 2. Comparison of eGFR Change Between Statin and Control Groups. A) Rate of eGFR Change Per Year (ml/min/1.73 m2), B) Total Change in
eGFR.
doi:10.1371/journal.pone.0132970.g002
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(LDL-C reduction = 24%-32%) and low- (LDL-C reduction = 25%) intensity statin therapy.
There were insufficient data to investigate effects of statins intensities on proteinuria.
Sensitivity Analysis
To assess the stability of the results of the meta-analysis of comparison in total change of eGFR
and rate of eGFR change, sensitivity analyses were conducted by excluding one study at a time.
None of the results was significantly altered, indicating that our results were robust.
Meta-regression
We performed meta-regression analysis using random-effects model to explore the effects of
covariates (percent reduction in LDL and baseline LDL) on differences in total change of
eGFR. Percent reduction in LDL-C was significant with a coefficient of -9.9 (95% CI: -18.2 to
-1.5), p = 0.02, and R2 = 60% (S4 Fig). In the model that explored effects of baseline LDL-C on
change in eGFR, it was a significant predictor with a coefficient of 0.04 (95% CI: 0.03 to 0.05,
p<0.01 and R2 = 98%.
Publication Bias
To investigate potential publication bias, we examined the contour-enhanced funnel plot of the
included studies in assessing total change in eGFR. Vertical axis represents study size (standard
error) while horizontal axis represents effect size (log odds ratio). From this plot, bias is not
present because there is symmetrical distribution of studies on both sides of the mean. The
results of Egger’s test suggest that no evidence of publication bias was observed (P = 0.58). The
funnel plot for assessing change in proteinuria was not performed due to too few studies.
Discussion
Summary of the Main Results
Overall, our systematic review and meta-analysis in CKD participants found that high-inten-
sity statin therapy [18,21] had a significantly less reduction in eGFR compared to control. The
Fig 3. Subgroup Analysis of Total Change in eGFR (ml/min/1.73 m2) in High, Moderate and Low Intensities Statin Groups.
doi:10.1371/journal.pone.0132970.g003
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total difference in eGFR was 3.35 ml/min/1.73 m2 in the high-intensity statin group compared
with control. However, we found no difference with moderate- and low-intensity statin therapy.
In addition, we did not find that statins lowered proteinuria compared to the control group.
Agreements and Disagreements with Other Studies or Reviews
Our findings are consistent with other meta-analysis in CKD participants not requiring dialysis
[25,26], which found marginal benefits of statins on change in GFR compared with controls.
However, those meta-analyses found a greater reduction of proteinuria in the statin group. We
believed that the difference in our findings could be due to a difference in inclusion and exclu-
sion criteria of eligible studies.
Previous meta-analyses of studies that reported renal function found that the effect of stat-
ins on eGFR may be dose-related in a general population [7]. However, our study is unique in
that our findings were specifically done in CKD participants with baseline eGFR less than 60
ml/min/1.73 m2. It is possible that CKD patients had greater baseline renovascular disease and
therefore required the greater effect of high intensity statins to provide a benefit on renal vascu-
lature and to reduce greater oxidative stress. In addition, we demonstrated that LDL-C reduc-
tion had a significant association with change in eGFR. There is an increased change of eGFR
with a greater reduction of LDL-C. This analysis helps to confirm a higher change of eGFR in
high-intensity statins that had greater reduction of LDL-C compared with moderate- and low-
intensity statins. Underlying mechanism of increased change of eGFR might be related to a
higher reduction of oxidized LDL particles that normally cause renal and vascular damage. We
also found an increased change of eGFR in higher baseline LDL-C. Higher baseline LDL-C
may cause more renal injury than lower LDL-C. More severe renal injury may benefits from
statin therapy more than lower injury [27,28].
Our findings are also unique in that we studied the effects of statin on hard end-points such
as ESRD or 50% reduction of eGFR. We did not find a significant association of statins and
these outcome. Our findings might be useful for clinicians to use high-intensity statin therapy
to slow deterioration in renal function in CKD patients. However, there are no clear benefits of
statin therapy on proteinuria. This might be because renal injury from lipotoxicity is indepen-
dent of proteinuria [29].
Strengths and Limitations
Strengths of our study include only enrolling CKD participants with a baseline eGFR less than
60 ml/min/1.73 m2 and a comprehensive MEDLINE, EMBASE and Cochrane Databases data-
base search. Also, we included only studies with a treatment duration of at least 6 months,
which allowed us to see the longer term effects of statins on renal function. In addition, we ana-
lyzed the difference in the change of renal function, and not only the end of treatment outcome
as in a previous meta-analysis examining this topic [26]. Furthermore, we did a subgroup anal-
ysis on statin intensity, which can keep answer whether statins may have a dose-response effect
in CKD patients.
There are several limitations in our meta-analysis, and thus our results should be interpreted
with caution. First, we included a relatively small number of studies. This is because we sepa-
rately analyzed studies with the outcome of total change in eGFR and rate of eGFR change per
year as they used different units and we did not have enough information to change them into
the same unit.
Second, there is high heterogeneity between studies in the meta-analysis of statins effect on
total change of eGFR. Potential sources of heterogeneity assessed by meta-regression were
study designs, baseline LDL-C, and LDL-C reduction. We found that there was an increased in
Statins in Chronic Kidney Disease
PLOS ONE | DOI:10.1371/journal.pone.0132970 July 7, 2015 10 / 13
total change of eGFR with a higher baseline LDL-C or with an increased in reduction of
LDL-C. This finding supports our main results of a significant effects of high-intensity statin.
Conclusions
Our results add evidence that statin use in CKD patients may delay progression of kidney dis-
ease, and our results suggest that statins may have a dose-related effect on kidney function as
only high-intensity statin significantly improved renal function assessed by estimated GFR.
However, these results should be interpreted with caution. Further RCT’s using different statin
intensities in CKD patients not requiring dialysis with a longer duration of study are needed.
Supporting Information
S1 Appendix. PRISMA checklist.
(DOC)
S2 Appendix. Search Strategy.
(DOCX)
S1 Fig. Risk of Bias of included studies. Review authors' judgments about each risk of bias.
Item presented as percentages across all RCT and Non-Randomized trials. Positive signs repre-
sent low risk of bias. Negative signs represent high risk of bias. Blank spaces represent unclear
risk.
(TIF)
S2 Fig. Comparison of Change in Urinary Protein Excretion Between Statin and Control
Groups.
(TIF)
S3 Fig. Comparison of Risk of A) 50% Reduction in eGFR and B) ESRD Between Statin
and Control Groups.
(TIF)
S4 Fig. Meta-Regression Scatter Plot of Studies Comparing Total Change in eGFR Using
Percent Reduction in LDL-C. Circles represent each included study.
(TIF)
Author Contributions
Conceived and designed the experiments: AS. Performed the experiments: AS SU. Analyzed
the data: AS SU. Contributed reagents/materials/analysis tools: WC PU. Wrote the paper: AS
EK.
References
1. James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of chronic kidney disease.
Lancet. 2010; 375(9722):1296–309. doi: 10.1016/S0140-6736(09)62004-3 PMID: 20382326
2. Sharma K, Ramachandrarao S, Qiu G, Usui HK, Zhu Y, Dunn SR, et al. Adiponectin regulates albumin-
uria and podocyte function in mice. J Clin Invest. 2008; 118(5):1645–56. doi: 10.1172/JCI32691 PMID:
18431508
3. Vidt DG, Harris S, McTaggart F, Ditmarsch M, Sager PT, Sorof JM. Effect of short-term rosuvastatin
treatment on estimated glomerular filtration rate. Am J Cardiol. 2006; 97(11):1602–6. PMID: 16728222
4. Douglas K, O'Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern
Med. 2006; 145(2):117–24. PMID: 16847294
Statins in Chronic Kidney Disease
PLOS ONE | DOI:10.1371/journal.pone.0132970 July 7, 2015 11 / 13
5. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-
analysis. Kidney Int. 2001; 59(1):260–9. PMID: 11135079
6. Zoja C, Corna D, Rottoli D, Cattaneo D, Zanchi C, Tomasoni S, et al. Effect of combining ACE inhibitor
and statin in severe experimental nephropathy. Kidney Int. 2002; 61(5):1635–45. PMID: 11967013
7. Geng Q, Ren J, Song J, Li S, Chen H. Meta-analysis of the effect of statins on renal function. Am J Car-
diol. 2014; 114(4):562–70. doi: 10.1016/j.amjcard.2014.05.033 PMID: 25001155
8. HouW, Lv J, Perkovic V, Yang L, Zhao N, Jardine MJ, et al. Effect of statin therapy on cardiovascular
and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis.
Eur Heart J. 2013; 34(24):1807–17. doi: 10.1093/eurheartj/eht065 PMID: 23470492
9. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA
guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a
report of the American College of Cardiology/American Heart Association Task Force on Practice
Guidelines. Circulation. 2014; 129(25 Suppl 2):S1–45. doi: 10.1161/01.cir.0000437738.63853.7a
PMID: 24222016
10. (KDIGO) KDIGO. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic
kidney disease. Kidney International. 2013; 3:1.
11. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observa-
tional studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epi-
demiology (MOOSE) group. JAMA. 2000; 283(15):2008–12. PMID: 10789670
12. Higgins JPT, Green S, Cochrane Collaboration. Cochrane handbook for systematic reviews of interven-
tions. Chichester, England; Hoboken, NJ: Wiley-Blackwell; 2008. xxi, 649 p. p.
13. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonran-
domized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603–5. doi: 10.1007/s10654-010-
9491-z PMID: 20652370
14. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J
Clin Epidemiol. 2001; 54(10):1046–55. PMID: 11576817
15. Yasuda G, Kuji T, Hasegawa K, Ogawa N, Shimura G, Ando D, et al. Safety and efficacy of fluvastatin
in hyperlipidemic patients with chronic renal disease. Ren Fail. 2004; 26(4):411–8. PMID: 15462110
16. Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC, Cholesterol, et al. Effect of pravastatin on loss of
renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am
Soc Nephrol. 2003; 14(6):1605–13. PMID: 12761262
17. Tonelli M, Isles C, Craven T, Tonkin A, Pfeffer MA, Shepherd J, et al. Effect of pravastatin on rate of kid-
ney function loss in people with or at risk for coronary disease. Circulation. 2005; 112(2):171–8. PMID:
15998677
18. Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorva-
statin on proteinuria and progression of kidney disease. Am J Kidney Dis. 2003; 41(3):565–70. PMID:
12612979
19. Kendrick J, Shlipak MG, Targher G, Cook T, Lindenfeld J, Chonchol M. Effect of lovastatin on primary
prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air
Force/Texas Coronary Atherosclerosis Prevention Study. Am J Kidney Dis. 2010; 55(1):42–9. doi: 10.
1053/j.ajkd.2009.09.020 PMID: 19932541
20. RahmanM, Baimbridge C, Davis BR, Barzilay J, Basile JN, Henriquez MA, et al. Progression of kidney
disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus
usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
(ALLHAT). Am J Kidney Dis. 2008; 52(3):412–24. doi: 10.1053/j.ajkd.2008.05.027 PMID: 18676075
21. Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A, Reed DP, et al. Focused atorvastatin
therapy in managed-care patients with coronary heart disease and CKD. Am J Kidney Dis. 2009; 53
(5):741–50. doi: 10.1053/j.ajkd.2008.11.025 PMID: 19216014
22. Sawara Y, Takei T, Uchida K, Ogawa T, Yoshida T, Tsuchiya K, et al. Effects of lipid-lowering therapy
with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease. Intern Med. 2008;
47(17):1505–10. PMID: 18758125
23. Natsuaki M, Furukawa Y, Morimoto T, Sakata R, Kimura T, Investigators CR-KPCRC. Renal function
and effect of statin therapy on cardiovascular outcomes in patients undergoing coronary revasculariza-
tion (from the CREDO-Kyoto PCI/CABGRegistry Cohort-2). Am J Cardiol. 2012; 110(11):1568–77. doi:
10.1016/j.amjcard.2012.07.021 PMID: 22935527
24. Haynes R, Lewis D, Emberson J, Reith C, Agodoa L, Cass A, et al. Effects of lowering LDL cholesterol
on progression of kidney disease. J Am Soc Nephrol. 2014; 25(8):1825–33. doi: 10.1681/ASN.
2013090965 PMID: 24790178
Statins in Chronic Kidney Disease
PLOS ONE | DOI:10.1371/journal.pone.0132970 July 7, 2015 12 / 13
25. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Hegbrant J, et al. HMGCoA reduc-
tase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. The Cochrane
database of systematic reviews. 2014; 5:CD007784. doi: 10.1002/14651858.CD007784.pub2 PMID:
24880031
26. Palmer SC, Navaneethan SD, Craig JC, Johnson DD, Perkovic V, Hegbrant J, et al. HMGCoA reduc-
tase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Sao Paulo Med J.
2014; 132(5):314–5.
27. Ruan XZ, Varghese Z, Moorhead JF. An update on the lipid nephrotoxicity hypothesis. Nature reviews
Nephrology. 2009; 5(12):713–21. doi: 10.1038/nrneph.2009.184 PMID: 19859071
28. Cases A, Coll E. Dyslipidemia and the progression of renal disease in chronic renal failure patients. Kid-
ney Int Suppl. 2005(99: ):S87–93. PMID: 16336584
29. Lee HS, Jeong JY, Kim BC, Kim YS, Zhang YZ, Chung HK. Dietary antioxidant inhibits lipoprotein oxi-
dation and renal injury in experimental focal segmental glomerulosclerosis. Kidney Int. 1997; 51(4):
1151–9. PMID: 9083281
Statins in Chronic Kidney Disease
PLOS ONE | DOI:10.1371/journal.pone.0132970 July 7, 2015 13 / 13
